SLC5A2 and diabetic kidney disease: Despite the advancements in treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists [2–4], patients with T2DM remain at risk of developing diabetic kidney disease (DKD), which is one of the top 10 causes of death globally [5].